The supplement industry generates over $50 billion annually, yet the vast majority of products on the market have little to no clinical evidence for their longevity claims. Navigating this landscape requires understanding not just which compounds have evidence, but what quality of evidence exists — a single mouse study is fundamentally different from multiple replicated human RCTs.
This category covers every supplement with credible relevance to longevity science. From well-established compounds like vitamin D, omega-3s, creatine, and magnesium — which have decades of human clinical trial data — to emerging compounds like NMN, spermidine, fisetin, and alpha-ketoglutarate — which have promising preclinical data but limited human evidence. Each article covers the mechanism of action, the complete clinical trial landscape (not just the positive studies), optimal dosing based on research, form and bioavailability considerations, interaction risks, and an honest assessment of where the evidence currently stands.